0
0

Agonist Maintenance Treatment

Richard S. Schottenfeld, M.D.

Sections

Excerpt

Opioid dependence is a chronic and severe disorder associated with substantial risk of mortality, morbidity, and adverse social, vocational, familial, and legal consequences. The goals of treatment are to prevent or reduce the adverse consequences and to improve the patient's functioning and quality of life. Opioid agonist maintenance treatment generally refers to a comprehensive approach, including medications in combination with drug counseling, behavioral monitoring, and provision of or referral to psychiatric, medical, or vocational services. Since its development in the 1960s, this approach has proven to be the most effective treatment for opioid dependence.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Table Reference Number
Table 14C–1. Medication interactions

References

Amato L, Minozzi S, Davoli M, et al: Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev (4):CD005031, 2004
 
Anglin MD, Speckart GR, Booth MW, et al: Consequences and costs of shutting off methadone. Addict Behav 14:307–326, 1989
[PubMed]
 
Archie C: Methadone in the management of narcotic addiction in pregnancy. Obstet Gynecol 10:435–440, 1998
[PubMed]
 
Avants SK, Margolin A, Kosten TR, et al: When is less treatment better? The role of social anxiety in matching methadone patients to psychosocial treatments. J Consult Clin Psychol 66:924–931, 1998
[PubMed]
 
Ball JC, Ross A: The Effectiveness of Methadone Maintenance Treatment. New York, Springer-Verlag, 1991
 
Compton P, Charuvastra VC, Ling W: Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 63:139–146, 2001
[PubMed]
 
Darke S, Swift W, Hall W, et al: Drug use, HIV risk-taking and psychosocial correlates of benzodiazepine use among methadone maintenance clients. Drug Alcohol Depend 34:67–70, 1993
 
Donny EC, Walsh SL, Bigelow GE, et al: High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology 161:202–212, 2002
[PubMed]
 
Dyer KR, Foster DJ, White JM, et al: Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 65:685–694, 1999
[PubMed]
 
Eap CB, Broly F, Mino A, et al: Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 21:229–234, 2001
[PubMed]
 
Fairbank JA, Dunteman GH, Condelli WS: Do methadone patients substitute other drugs for heroin? Predicting substance use at 1-year follow-up. Am J Drug Alcohol Abuse 19:465–474, 1993
[PubMed]
 
Fiellin DA, O'Connor PG, Chawarski M, et al: Methadone maintenance in primary care: a randomized controlled trial. JAMA 286:1724–1731, 2001
[PubMed]
 
Foster DJ, Somogyi AA, Dyer KR, et al: Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 50:427–440, 2001
 
Gutstein HB, Akil H: Opioid analgesics, in Goodman and Gilman's The Pharmacological Basis of Therapeutics. Edited by Hardman JG, Limbird LL. New York, McGraw-Hill, 2001, pp 569–619
 
Hser YI, Hoffman V, Grella CE, et al: A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 58:503–508, 2001
[PubMed]
 
Hubbard RL, Craddock SG, Flynn PM, et al: Overview of 1 year follow-up outcomes in Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav 11:261–278, 1997
 
Krantz MJ, Lewkowiez L, Hays H, et al: Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 137:501–504, 2002
[PubMed]
 
Kreek MJ: Methadone-related opioid agonist pharmacotherapy for heroin addiction: history, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci 909:186–216, 2000
[PubMed]
 
McLellan AT, Arndt IO, Metzger DS, et al: The effects of psychosocial services in substance abuse treatment. JAMA 269:1953–1959, 1993
[PubMed]
 
Metzger DS, Woody GE, McLellan AT, et al: Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 6:1049–1056, 1993
[PubMed]
 
Murrill CS, Weeks H, Castrucci BC, et al: Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health 92:385–387, 2002
[PubMed]
 
Nunes EV, Quitkin FM, Donovan SJ, et al: Imipramine treatment of opiate-dependent patients with depressive disorders: a placebo-controlled trial. Arch Gen Psychiatry 55:153–160, 1998
[PubMed]
 
Rainey PM: HIV drug interactions: the good, the bad, and the other. Ther Drug Monit 24:26–31, 2002
[PubMed]
 
Schottenfeld RS, Chawarski MC, Pakes JR, et al: Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 162:340–349, 2005
[PubMed]
 
Sees KL, Delucchi KL, Masson C, et al: Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 283:1303–1310, 2000
[PubMed]
 
Strain EC, Bigelow GE, Liebson IA, et al: Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial [see comments]. JAMA 281:1000–1005, 1999
[PubMed]
 
Wines JD Jr, Weiss RD: Opioid withdrawal during risperidone treatment. J Clin Psychopharmacol 19:265–267, 1999
[PubMed]
 
Wolff K: Characterization of methadone overdose: clinical considerations and the scientific evidence. Ther Drug Monit 24:457–470, 2002
[PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 9.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 12.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 25.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 44.  >
Psychiatric News
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation